Show simple item record

dc.contributor.authorCarrillo-Gálvez, Ana Belén
dc.contributor.authorQuintero, Juan Esteban
dc.contributor.authorRodríguez, René
dc.contributor.authorMenéndez, Sofía T.
dc.contributor.authorGonzález, M. Victoria
dc.contributor.authorBlanco-Lorenzo, Verónica
dc.contributor.authorAllonca, Eva
dc.contributor.authorFarias, Virgínea de Araújo
dc.contributor.authorGonzález-Correa, Juan Elías
dc.contributor.authorErill-Sagalés, Nadina
dc.contributor.authorMartínez-Zubiaurre, Iñigo
dc.contributor.authorHellevik, Turid
dc.contributor.authorSánchez-Hernández, Sabina
dc.contributor.authorMuñoz, Pilar
dc.contributor.authorZurita, Federico
dc.contributor.authorMartín, Francisco
dc.contributor.authorRodríguez-Manzaneque, Juan Carlos
dc.contributor.authorAnderson, Per
dc.date.accessioned2021-05-03T07:30:22Z
dc.date.available2021-05-03T07:30:22Z
dc.date.issued2020-11-17
dc.description.abstractSarcomas are mesenchymal cancers with poor prognosis, representing about 20% of all solid malignancies in children, adolescents, and young adults. Radio- and chemoresistance are common features of sarcomas warranting the search for novel prognostic and predictive markers. GARP/LRRC32 is a TGF-β-activating protein that promotes immune escape and dissemination in various cancers. However, if GARP affects the tumorigenicity and treatment resistance of sarcomas is not known. We show that GARP is expressed by human osteo-, chondro-, and undifferentiated pleomorphic sarcomas and is associated with a significantly worse clinical prognosis. Silencing of GARP in bone sarcoma cell lines blocked their proliferation and induced apoptosis. In contrast, overexpression of GARP promoted their growth in vitro and in vivo and increased their resistance to DNA damage and cell death induced by etoposide, doxorubicin, and irradiation. Our data suggest that GARP could serve as a marker with therapeutic, prognostic, and predictive value in sarcoma. We propose that targeting GARP in bone sarcomas could reduce tumour burden while simultaneously improving the efficacy of chemo- and radiotherapy.en_US
dc.identifier.citationCarrillo-Gálvez AB, Quintero JE, Rodríguez R, Menéndez ST, González MV, Blanco-Lorenzo V, Allonca E, Farias VA, González-Correa JE, Erill-Sagalés N, Martínez-Zubiaurre I, Hellevik T, Sánchez-Hernández S, Muñoz P, Zurita F, Martín F, Rodríguez-Manzaneque JC, Anderson P. GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-beta. Cell Death and Differentiation. 2020en_US
dc.identifier.cristinIDFRIDAID 1832365
dc.identifier.doi10.1038/s41419-020-03197-z
dc.identifier.issn1350-9047
dc.identifier.issn1476-5403
dc.identifier.urihttps://hdl.handle.net/10037/21111
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.journalCell Death and Differentiation
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2020 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleGARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-betaen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record